

Zantac Lawsuits

Results achieved in prior matters are not meant to be a guarantee of success as the facts and legal circumstances vary from matter to matter.

While we no longer handle Zantac cases, we continue to advocate for clients in related areas. Visit our <u>Defective Drugs and Device Injuries page</u> to view all of the current cases we are handling.

FDA Requests Recall of Ranitidine (brand name Zantac) Products

On April 1, 2020, the U.S. Food and Drug Administration (FDA) requested that all prescription and over-the-counter ranitidine (brand name Zantac) products be withdrawn from the market immediately. Zantac belongs to a class of drugs called H2 blockers. Zantac was used to prevent and treat heartburn, acid reflux, and other symptoms caused by excess acid produced in the stomach.

Findings Reveal Unsafe Levels of N-Nitrosodimethylamine (NDMA)

The FDA's request for an immediate recall resulted from findings that certain ranitidine products contained N-Nitrosodimethylamine (NDMA). NDMA has been classified as a probable human carcinogen. Testing has determined that under certain circumstances, NDMA levels in ranitidine products increase under normal storage conditions. Research has shown NDMA levels increase significantly when stored at higher temperatures and over time.

NDMA has been linked with certain cancers including:

- Bladder Cancer
- Pancreatic Cancer
- Stomach Cancer
- Colorectal Cancer
- Liver Cancer
- And other Cancers